Personal Profile

Dr. Wang Qin graduated from the Clinical Medicine Department of the former Zhongshan Medical University in 1999, obtaining a Bachelor of Medicine degree. In the same year, she was recommended without examination to pursue a master's degree in the Department of Pharmacology at Zhongshan Medical University and obtained her master's degree in 2002. In 2003, she went to the Department of Applied Biology and Chemical Technology at the Hong Kong Polytechnic University to pursue a Ph.D. degree. After obtaining her Ph.D. degree in July 2007, she returned to China to work. She is currently the Party Branch Secretary, Professor, and Doctoral Supervisor in the Department of Pharmacology and Pathophysiology at Zhongshan School of Medicine, Sun Yat-sen University.

Research Directions

Her current research directions include:
(1) Study on the role of gap junction channels and connexins in tumorigenesis and development;
(2) Study on the influence of gap junctions on the development of drug resistance to anticancer drugs and its mechanisms;
(3) Preclinical pharmacodynamic evaluation of new drugs.

Academic Achievements
Important Academic Research Results and Contributions

Since returning to China, Dr. Wang Qin has mainly focused on the study of the role and mechanisms of gap junctions in tumorigenesis, development, and the development of drug resistance to anticancer drugs. Her current research directions include:
(1) Study on the role of gap junction channels and connexins in tumorigenesis and development;
(2) Study on the influence of gap junctions on the development of drug resistance to anticancer drugs and its mechanisms;
(3) Preclinical pharmacodynamic evaluation of new drugs.

Dr. Wang Qin has presided over 3 National Natural Science Foundation projects, 5 provincial-level scientific research projects, and 4 key projects at the university level. She has also led 3 corporate-sponsored scientific research projects. Meanwhile, as the third-ranked sub-project leader, she participated in 1 key project of the National Natural Science Foundation - Xinjiang Joint Fund. As the second applicant (ranked second), she participated in the research work of 3 general projects of the National Natural Science Foundation. In addition, she also participated as a major contributor in the National "Major New Drug Creation" Science and Technology Major Project - "Construction of Preclinical Pharmacodynamic Evaluation Technology Platform for New Drugs" and 2 local preclinical evaluation technology platform construction projects.

In recent years, Dr. Wang Qin has published more than 70 research papers in high-level domestic and international journals such as Journal of Experimental & Clinical Cancer Research, Cancer Lett., and Pharmaceutics. Among them, she has 38 SCI articles as the first author or corresponding author.

Since 2009, Dr. Wang Qin has presided over or participated in the completion of more than 30 preclinical pharmacodynamic evaluation projects for new drugs. In 2011, she led a preclinical pharmacodynamic evaluation project for a national Class I new anticancer drug commissioned by Zhejiang Hisun Pharmaceutical Co., Ltd. to our university. This drug obtained the new drug clinical trial certificate issued by the National SFDA in 2014 and began clinical trials.

Academic Works

1. Shaoyi Caia, Fuhua Penga, Heng Tanga, Liping Zhou, Zhiyou Chen, Penghan Wu,
   Yueling Ou, Liang Tao, Qin Wang. A new IRES-mediated truncated Cx32 isoform inhibits global mRNA translation to suppress glioblastoma. Biomed Pharmacother. 2023 May;161:114513.
2. Qian Y, Ni W, Xianyu X, Tao L, WangQ. DoubleSG-DTA: deep learning for drug discovery: case study on the non-small cell lung cancer with EGFRT 790 M mutation. Pharmaceutics. 2023 Feb 16;15(2):675.
3.  Yang F, Chen X, Zhang H, Zhao GD, Yang H, Qiu J, Meng S, Wu P, Tao L, Wang Q, Huang G.Single-Cell Transcriptome Identifies the Renal Cell Type Tropism of Human BK Polyomavirus. Int J Mol Sci. 2023 Jan 10;24(2):1330. 
4. Cai S, Chen Z, Tang H, Meng S, Tao L, Wang Q. Upregulated FKBP1A Suppresses Glioblastoma Cell Growth via Apoptosis Pathway. Int J Mol Sci. 2022 Nov 29;23(23):14935.
5. Yang F, Zhao Z, Zhang H, Zhou L, Tao L , Wang Q . Concentration-dependent transcriptome of zebrafish larvae for environmental bisphenol S assessment. Ecotoxicol Environ Saf. 2021 Oct 15;223:112574.
6. Yang F, Zhao ZY, Cai SY, Ling L, Hong LY, Tao L, Wang Q. Detailed molecular mechanism and potential drugs for COL1A1 in carboplatin-resistant ovarian cancer . Frontiers in Oncology,2021 Feb 17;10:576565.  
7. XiangYK, Peng FH, Guo YQ, Ge H, Cai SY, Fan LX, Peng YX, Wen H, Wang Q(共同通讯作者), Tao L. Connexin32 activates necroptosis through Src-mediated inhibition of caspase 8 in hepatocellular carcinoma[J]. Cancer Science ,2021,112(9):3507-3519.
8. Fan LX, Zheng NZ, Peng FH, Zhao ZY, Fan D, Cai SY, Tao L, Wang Q. Nitric Oxide Affects Cisplatin Cytotoxicity Oppositely in A2780 and A2780-CDDP Cells via the connexin32/gap Junction. Cancer Science, 2020, 111 (8):2779-2788.
9. Fu YL, Peng FH, Zheng NZ, Lin Q, Cai SY, Wang Q. GJA1-20k attenuates Ang II-induced pathological cardiac hypertrophy by regulating gap junction formation and mitochondrial function[J]. Acta Pharmacologica sinica, 2020, 42(4) :536-549.  
10. Xiang YK, Wang Q（共同第一）, Guo YQ, Ge H, Fu YL, Wang XY, Tao L. Cx32 exerts anti-apoptotic and pro-tumor effects via the epidermal growth factor receptor pathway in hepatocellular carcinoma. Journal of Experimental&Clinical Cancer Research, 2019,38(1):145.
11. Hong XT, Wand Q（共同第一）, Yang Y, Zhang SP, Tong XH, Zhang SZ, Tao L, Harris AL.. Gap Junctions Propagate Opposite Effects in Normal and Tumor Testicular Cells in Response to Cisplatin. Cancer Letters, 2012, 317(2):165-171. 
12. He B, Tong X, Wang L, Wang Q, Ye H, Liu B, Hong X, Tao L, Harris AL. Tramadol and  flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clinical Cancer Research, 2009, 15(18):5803-10.